Blood pressure guidelines in chronic kidney disease: A critical review

Nephron - Clinical Practice

Volumn 113, Issue 4, 2009, Pages

  Thuraisingham, R C ^a   Yaqoob, M M ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Cardiovascular diseases; Guidelines; Progression of chronic kidney disease; Standards

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG CHOICE; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; GERMANY; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 69549112674     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235947     Document Type: Short Survey

References (43)

1. Uhlig K, Balk EM, Lau J, Levey AS: Clinical practice guidelines in nephrology - for worse or for better. Nephrol Dial Transplant 2006; 21: 1145-1153.
2. Strippoli GF, Craig JC, Schena FP: The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 2004; 15: 411-419.
3. Coyne DW: Influence of industry on renal guideline development. Clin J Am Soc Nephrol 2007; 2: 3-7.
4. Renal Association: Treatment of Adults and Children with Renal Failure: Standards and Audit Measures, ed 3. London, Royal College of Physicians of London and the Renal Association, 2002.
5. Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185. (Pubitemid 38425770)
6. McIntosh A, Hutchinson A, Marshall S, et al: Clinical guidelines and evidence review for type 2 diabetes. Renal disease: Prevention and early management. Sheffield, ScHARR, University of Sheffield, 2002. Royal College of General Practitioners. http://www.rcgp.org.uk/ (accessed March 1, 2005).
7. American Diabetes Association: Standards of medical care in diabetes, 2005. Diabetes Care 2005; 28(suppl 1):S4-S36.
8. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2572.
9. Palmer BF. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(suppl 1):S1-S290.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252. (Pubitemid 37553153)
11. Palmer BF: Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am J Med 2008; 121(suppl 8): S16-S22.
12. Hart PD, Bakris GL: Managing hypertension in the diabetic patient; in Egan BM, Basile JN, Lackland DT (eds): Hot Topic in Hypertension. Philadelphia, Hanley & Belfus, 2004, pp 249-252.
13. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ; the Collaborative Study Group: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809-817.
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23(suppl 2):SB54-SB64.
15. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
16. Estacio RO, Coll JR, Tran ZV, Schrier RW: Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006; 19: 1241-1248.
17. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001;285: 2719-2728.
18. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G; for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
19. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, et al: Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomized controlled trial. Lancet 2005; 365: 939-946.
20. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179.
21. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE: Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant 2006; 21: 1257-1262.
22. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ: Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884-893.
23. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355: 253-259.
24. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
25. Lewis EJ, Hunsicker LG, Clarke WR, et al; the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
26. EURopean Trial: On reduction of cardiac events with perindopril in stable coronary artery disease investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
27. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. N Engl J Med 2000; 342: 145-153.
28. PROGRESS Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
29. Weber MA, Julius S, Kjeldsen SE, et al: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051.
30. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.
31. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
32. Giatras I, Lau J, Levey AS; Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337-345.
33. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC: Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 2004; 329: 828.
34. Casas JP, Chua W, Loukgeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
35. Rahman M, Pressel S, Davis BR, et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker versus a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936-946.
36. Suissa S, Hutchinson T, Brophy JM, Kezouh A: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
37. Onuigbo MA, Onuigbo NT: Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol 2008; 40: 233-239.
38. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
39. Wright JT Jr, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, Randall O, Rogers N, Smith MC, Massry S: Successful blood pressure control in the African-American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1643.
40. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216.
41. Peralta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Feng L, Shlipak MG: Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005; 45: 1-6.
42. Peralta CA, Shlipak MG, Wassel-Fyr C, Bosworth H, Hoffman B, Martins S, Oddone E, Goldstein MK: Association of antihypertensive therapy and diastolic hypotension in chronic kidney disease. Hypertension 2007; 50: 474-480.
43. Couser WG: Chronic kidney disease - the promise and the perils. J Am Soc Nephrol 2007; 18: 2803-2805.